alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 73 Introduced in House (IH)]

<DOC>

118th CONGRESS
  1st Session
                                 H. R. 73

     To prohibit the use of Federal funds for the HHS Reproductive 
                     Healthcare Access Task Force.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            January 9, 2023

  Mr. Biggs introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
     To prohibit the use of Federal funds for the HHS Reproductive 
                     Healthcare Access Task Force.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``No Pro-Abortion Task Force Act''.

SEC. 2. PROHIBITION AGAINST USE OF FEDERAL FUNDS FOR HHS REPRODUCTIVE 
              HEALTHCARE ACCESS TASK FORCE.

    No Federal funds may be used for--
            (1) the HHS Reproductive Healthcare Access Task Force, 
        announced by the Secretary of Health and Human Services on 
        January 21, 2022; or
            (2) any successor or substantially similar task force.
                                 <all>
```
§ 333.101 Scope. ( a ) An over-the-counter first aid antibiotic drug product in a form suitable for topical administration is generally recognized as safe and effective and is not misbranded if it meets each of the conditions in this subpart and each of the general conditions established in § 330.1.
( b ) References in this subpart to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.
Exhibit 4.39

 

Letter of Undertakings

 

Leo Ou Chen, Tianjin Cyril Information and Technology Co., Ltd. (“Tianjin Cyril”) and Chengdu Li’ao Culture Communication Co., Ltd. (“Chengdu Li’ao”) entered into an EQUITY PLEDGE AGREEMENT on July 1, 2016. According to the agreement, Leo Ou Chen pledged all of his equity interests in Chengdu Li’ao to Tianjin Cyril and undertake to waive his right to receive any form of dividends with respect to such equity interests throughout the valid term of the Equity Pledge.

 

 

	
Leo   Ou Chen
    	
 
    
	
 
    	
 
    
	
Signature:
    	
/s/ Leo Ou Chen
    	
 
    
	
 
    	
 
    
	
July 1, 2016
[No. 21962-0-II.

Division Two.

December 31, 1997.]

#### The State of Washington, *Respondent,*v. Rayford J. Martin, *Appellant.*

Appeal from a judgment of the Superior Court for Clallam County, No. 96-1-00325-4, Kenneth D. Williams, J., entered April 16, 1997. *Affirmed*by unpublished opinion per Morgan, J., concurred in by Seinfeld and Armstrong, JJ.
§ 358.510 Corn and callus remover active ingredients. The product consists of any of the following active ingredients within the specified concentrations and in the dosage form established for each ingredient. ( a ) Salicylic acid 12 to 40 percent in a plaster vehicle.
( b ) Salicylic acid 12 to 17.6 percent in a collodion-like vehicle.
#### § 332.15 Combination with non-antiflatulent active ingredients.

An antiflatulent may contain any generally recognized as safe and effective antacid ingredient(s) if it is indicated for use solely for the concurrent symptoms of gas associated with heartburn, sour stomach or acid indigestion.
Editorial Note on Part 170
Editorial Note: Nomenclature changes to part 170 appear at 66 FR 56035, Nov. 6, 2001, and 69 FR 13717, Mar. 24, 2004.

§ 170.20 General principles for evaluating the safety of food additives. ( a ) In reaching a decision on any petition filed under section 409 of the Act, the Commissioner will give full consideration to the specific biological properties of the compound and the adequacy of the methods employed to demonstrate safety for the proposed use, and the Commissioner will be guided by the principles and procedures for establishing the safety of food additives stated in current publications of the National Academy of Sciences-National Research Council. A petition will not be denied, however, by reason of the petitioner's having followed procedures other than those outlined in the publications of the National Academy of Sciences-National Research Council if, from available evidence, the Commissioner finds that the procedures used give results as reliable as, or more reliable than, those reasonably to be expected from the use of the outlined procedures. In reaching a decision, the Commissioner will give due weight to the anticipated levels and patterns of consumption of the additive specified or reasonably inferrable. For the purposes of this section, the principles for evaluating safety of additives set forth in the abovementioned publications will apply to any substance that may properly be classified as a food additive as defined in section 201(s) of the Act.
( b ) Upon written request describing the proposed use of an additive and the proposed experiments to determine its safety, the Commissioner will advise a person who wishes to establish the safety of a food additive whether he believes the experiments planned will yield data adequate for an evaluation of the safety of the additive.
EXHIBIT 31.1
 
 EXCHANGE ACT RULE 13a-14(a) CERTIFICATION
 (Principal Executive Officer)
 
 I, Thomas G. Hood, certify that:
 
 1.
I have reviewed this quarterly report on Form 10-Q of Southwall Technologies Inc.; 
 2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 
 3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 
 4.
The chief financial officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: 
 (a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 
 (b)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 
 (c)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 
 5.
The chief financial officer and I have disclosed, based on our most recent valuation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): 
 (a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,summarize and report financial information; and 
 (b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 11th, 2004/s/ Thomas G. HoodThomas G. HoodChief Executive Officer
**EXHIBIT 21.1**

SUBSIDIARIES AS OF DECEMBER 31, 2002

| **Name**                           |   | **Jurisdiction of Incorporation** |           | **Percent Ownership** |
|------------------------------------|--------|-----------------------------------|----------------|-----------------------|
|                                    |   |                                   |           |                       |
| GolfWeb                            |   |                              | California     |                  | 100% |
| Sports.com Limited                 |   |                              | United Kingdom |                  | 38% |
| Commissioner.com, Inc.             |   |                              | New York       |                  | 100% |
| VegasInsider.com, Inc.             |   |                              | Delaware       |                  | 100% |
| Las Vegas Sports Consultants, Inc. |   |                              | Nevada         |                  | 100%* |
| MVP.com Sports, Inc.               |   |                              | Delaware       |                  | 100% |
| SBX Acquisition Corp.              |   |                              | Delaware       |                  | 100% |

*   Las Vegas Sports Consultants, Inc. is100% owned by VegasInsider.com, Inc.
#### § 1271.330 Applicability.

The provisions set forth in this subpart are being implemented for nonreproductive HCT/Ps described in § 1271.10 and regulated solely under section 361 of the Public Health Service Act and the regulations in this part, and for the establishments that manufacture those HCT/Ps. HCT/Ps that are drugs or devices regulated under the act, or are biological products regulated under section 351 of the Public Health Service Act, are not subject to the regulations set forth in this subpart.
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Page 8978]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3933]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Eunice Kennedy Shriver National Institute of Child Health & Human 
Development; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel, Population Research 
Infrastructure Program.
    Date: March 24, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military 
Road, NW., Washington, DC 20015.
    Contact Person: Carla T. Walls, PhD, Scientific Review Officer, 
Division of Scientific Review, Eunice Kennedy Shriver National 
Institute of Child Health and Human Development, NIH, 6100 Executive 
Blvd., Room 5B01, Bethesda, MD 20892, (301) 435-6898, 
<a href="/cdn-cgi/l/email-protection#7c0b1d10100f1f3c111d151052121514521b130a"><span class="__cf_email__" data-cfemail="750214191906163518141c195b1b1c1d5b121a03">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, 
Population Research; 93.865, Research for Mothers and Children; 
93.929, Center for Medical Rehabilitation Research; 93.209, 
Contraception and Infertility Loan Repayment Program, National 
Institutes of Health, HHS)

    Dated: February 19, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-3933 Filed 2-25-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<PAGE>   1



                                                                    Exhibit 23.1



                         CONSENT OF ARTHUR ANDERSEN LLP



As independent certified public accountants, we hereby consent to the
incorporation by reference of our report dated January 25, 1999 (except with
respect to the matter discussed in Note 5, as to which the date is February 10,
1999) on the consolidated financial statements of SportsLine USA, Inc. and
subsidiaries into the Company's previously filed registration statements on Form
S-8 (registration nos. 333-46021, 333-46023 and 333-46029).


Arthur Andersen LLP


Fort Lauderdale, Florida,
  March 12, 1999.
§ 522.1010 Furosemide. ( a ) *Specifications.* ( 1 ) Each milliliter (mL) of solution contains 50 milligrams (mg) furosemide monoethanolamine.
( 2 ) Each mL of solution contains 50 mg furosemide diethanolamine.
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter for use of products described in paragraph (a) of this section for use as in paragraph (d) of this section. ( 1 ) No. 000010 as described in paragraph (a)(1) of this section for use as in paragraphs (d)(1) and (d)(2)(ii) of this section.
( 2 ) No. 061133 as described in paragraph (a)(2) of this section for use as in paragraph (d)(2)(ii) of this section.
( 3 ) No. 058198 as described in paragraph (a)(2) of this section for use as in paragraphs (d)(1), (d)(2)(i), and (d)(3) of this section.
( 4 ) No. 000061 as described in paragraph (a)(2) for use as in paragraphs (d)(1), (d)(2)(iii), and (d)(3) of this section.
( c ) *Special considerations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( d ) *Conditions of use* — ( 1 ) *Dogs and cats* — ( i ) *Amount.* 1.25 to 2.5 mg per pound (/lb) body weight once or twice daily, intramuscularly or intravenously.
( ii ) *Indications for use.* For the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.
( 2 ) *Horses* — ( i ) *Amount.* 250 to 500 mg per animal once or twice daily, intramuscularly or intravenously. ( A ) *Indications for use.* For the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency, and acute noninflammatory tissue edema.
( B ) *Limitations.* Do not use in horses intended for human consumption.
( ii ) *Amount.* 0.5 mg/lb body weight once or twice daily, intramuscularly or intravenously. ( A ) *Indications for use.* For treatment of acute noninflammatory tissue edema.
( B ) *Limitations.* Do not use in horses intended for human consumption.
( iii ) *Amount.* 250 to 500 mg/animal once or twice daily, intramuscularly or intravenously. ( A ) *Indications for use.* For the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency, and acute noninflammatory tissue edema.
( B ) *Limitations.* Do not use in horses intended for human consumption.
( 3 ) *Cattle* — ( i ) *Amount.* 500 mg/animal once daily, intramuscularly or intravenously; or 250 mg/animal twice daily at 12-hour intervals, intramuscularly or intravenously.
( ii ) *Indications for use.* For the treatment of physiological parturient edema of the mammary gland and associated structures.
( iii ) *Limitations.* Treatment not to exceed 48 hours post-parturition. Milk taken during treatment and for 48 hours (four milkings) after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment.
[66 FR 47961, Sept. 17, 2001, as amended at 67 FR 18086, Apr. 15, 2002; 68 FR 59881, Oct. 20, 2003; 69 FR 17585, Apr. 5, 2004; 71 FR 39548, July 13, 2006; 74 FR 61516, Nov. 25, 2009; 76 FR 17338, Mar. 29, 2011; 78 FR 17597, Mar. 22, 2013; 79 FR 16189, Mar. 25, 2014; 84 FR 8973, Mar. 13, 2019; 86 FR 14820, Mar. 19, 2021]
<PAGE>
 
                                  Exhibit 23
                       Consent of KPMG Peat Marwick LLP


The Board of Directors
The Guarantee Life Companies Inc.

We consent to incorporation by reference in the registration statement (No.
333-41729) on Form S-3/A and registration statements (No.'s 333-17863 and
333-22461) on Form S-8 of The Guarantee Life Companies Inc. of our report dated
February 16, 1999, relating to the consolidated balance sheets of The Guarantee
Life Companies Inc. and subsidiaries as of December 31, 1998 and 1997, and the
related consolidated statements of income, comprehensive income, shareholders'
equity and cash flows for each of the years in the three-year period ended
December 31, 1998, and all related schedules, which report appears in the
December 31, 1998, annual report on Form 10-K of The Guarantee Life Companies
Inc.

                                                      KPMG Peat Marwick LLP

Omaha, Nebraska
February 16, 1999
<PAGE>   1

                                                                    EXHIBIT 23.1


                        CONSENT OF INDEPENDENT AUDITORS

We consent to the incorporation by reference, in the Registration Statements
(Form S-1 No. 333-45915) (Forms S-3 No. 333-70871, No. 333-78097, No.
333-83307, No. 333-70885 and No. 333-32760) and (Forms S-8 No. 333-45669, No.
333-47573, No. 333-81267 and No. 333-40126) of our report dated April 5, 2001
with respect to the consolidated financial statements and schedule of Global
TeleSystems, Inc., included in this Annual Report (Form 10-K) for the year
ended December 31, 2000.

                                          /s/ Ernst & Young
                                          Ernst & Young

London, England
April 11, 2001
OSLDPS Information Bulletin

No. 00-010 July 27, 2000

TO: All State Administrative Agency Heads

All State Administrative Agency Points of Contact

FROM: C.H. Straub II

Director

SUBJECT: State Strategy Technical Assistance Fact Sheet

Under the State and Local Domestic Preparedness Technical Assistance Program, the Office for

State and Local Domestic Preparedness Support (OSLDPS) has implemented a State Strategy

Technical Assistance component to assist states in meeting the needs assessment and

comprehensive planning requirements under the OSLDPS’ Fiscal Year 1999 State Domestic

Preparedness Equipment Support Program.

State Strategy Technical Assistance provides three distinct training sessions to better prepare state

and local jurisdictions in developing and implementing a three-year state strategy. These are:

Understanding and Implementing the Assessment Process, How to Conduct Assessments at

the Jurisdictional Level, and Developing a State Strategy.

Attached is a copy of the State Strategy Technical Assistance Fact Sheet, which describes the

program goals, technical assistance sessions, and how to request technical assistance.

All questions regarding technical assistance can be directed to Gabrielle Meszaros-Parada,

Technical Assistance Coordinator, OSLDPS, at telephone: (202) 307-6061, Fax (202) 616-2922

or email: Meszaros@ojp.usdoj.gov
axdx_ex10136.htm

EXHIBIT 10.13.6





  

 

AMENDMENT 

TO

12% REVOLVING LINE OF CREDIT PROMISSORY NOTE DUE 2016

 

OF

 

CO-DIAGNOSTICS, INC.

 

Original Principal Amount: $50,000

Original Issuance Date: May 30, 2016 

 

Whereas, THIS AMENDMENT TO THE 12% PROMISSORY NOTE dated May 30, 2016, as amended (the “Note”) is entered into, by and between Co-Diagnostics, Inc., a Utah corporation (the “Company”) and Machan 1988 Property Trust (“Holder”);

 

Now therefore, the Note is hereby amended as follows:

 

The Maturity Date shall be September 30, 2017.

 

All other terms and conditions of the Note, as amended, shall continue in full force and effect. 

 

IN WITNESS WHEREOF, the Parties have amended the Note effective as of September 14, 2016.

 

 


	
CO-DIAGNOSTICS, INC. 
	
 
	
MACHAN 1988 PROPERTY TRUST

	
 
	
 
	
 

	
By: /s/ Dwight Egan
	
 
	
By: /s/ Reed Benson 

	
Dwight H. Egan 
	
 
	
 

	
President & CEO 
	
 
	
Its: Trustee
#### § 251.20 Severability.

The provisions of this part are not separate and are not severable from one another. If any provision is stayed or determined to be invalid or unenforceable, the remaining provisions shall not continue in effect.
<TABLE> <S> <C>


<ARTICLE>                     9
<LEGEND>

               This schedule  contains summary financial  information  extracted
          from the balance sheet dated 12/31/99 and statement of income
          for the twelve months ended  12/31/99 and is qualified in its entirety
          by reference to such financial statements.
</LEGEND>
<CIK>                              0000945434
<NAME>                             BNCCORP, INC.
<MULTIPLIER>                       1000
<CURRENCY>                         U.S. DOLLARS

<S>                                <C>
<PERIOD-TYPE>                      12-MOS
<FISCAL-YEAR-END>                  DEC-31-1999
<PERIOD-START>                     JAN-01-1999
<PERIOD-END>                       DEC-31-1999
<EXCHANGE-RATE>                    1
<CASH>                             12,816
<INT-BEARING-DEPOSITS>             5,565
<FED-FUNDS-SOLD>                   3,500
<TRADING-ASSETS>                   0
<INVESTMENTS-HELD-FOR-SALE>        150,992
<INVESTMENTS-CARRYING>             0
<INVESTMENTS-MARKET>               0
<LOANS>                            262,051
<ALLOWANCE>                        2,872
<TOTAL-ASSETS>                     456,877
<DEPOSITS>                         324,711
<SHORT-TERM>                       88,700
<LIABILITIES-OTHER>                5,847
<LONG-TERM>                        14,470
<PREFERRED-MANDATORY>              0
<PREFERRED>                        0
<COMMON>                           24
<OTHER-SE>                         23,125
<TOTAL-LIABILITIES-AND-EQUITY>     456,877
<INTEREST-LOAN>                    22,083
<INTEREST-INVEST>                  6,739
<INTEREST-OTHER>                   109
<INTEREST-TOTAL>                   28,931
<INTEREST-DEPOSIT>                 12,537
<INTEREST-EXPENSE>                 16,574
<INTEREST-INCOME-NET>              12,357
<LOAN-LOSSES>                      1,138
<SECURITIES-GAINS>                 198
<EXPENSE-OTHER>                    18,215
<INCOME-PRETAX>                    (928)
<INCOME-PRE-EXTRAORDINARY>         (529)
<EXTRAORDINARY>                    867
<CHANGES>                          (96)
<NET-INCOME>                       242
<EPS-BASIC>                      .10
<EPS-DILUTED>                      .10
<YIELD-ACTUAL>                     7.99
<LOANS-NON>                        1,620
<LOANS-PAST>                       22
<LOANS-TROUBLED>                   16
<LOANS-PROBLEM>                    3,942
<ALLOWANCE-OPEN>                   2,854
<CHARGE-OFFS>                      1,290
<RECOVERIES>                       170
<ALLOWANCE-CLOSE>                  2,872
<ALLOWANCE-DOMESTIC>               2,665
<ALLOWANCE-FOREIGN>                0
<ALLOWANCE-UNALLOCATED>            207



</TABLE>
Argued and submitted November 3,

reversed and remanded November 24, 1999

#### STATE OF OREGON, *Appellant, v.*MOLLY ATKINSON, *Respondent.*

(CR97-50863; CA A103194)

991 P2d 578

Katherine H. Waldo, Assistant Attorney General, argued the cause for appellant. With her on the brief were Hardy Myers, Attorney General, and Michael D. Reynolds, Solicitor General.

J. Michael Alexnder argued the cause, for respondent. With him on the brief was Burt, Swanson, Lathen, Alexander & McCann, P.C.

Before De Muniz, Presiding Judge, and Haselton and Wollheim, Judges.

PER CURIAM

Reversed and remanded. *State v. Gaffney,*36 Or App 105, 583 P2d 582 (1978), *rev den*285 Or 195 (1979).